Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function-Reference-Cited by-同舟云学术

Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function

Published:2021-08-10 Issue:4 Volume:2 Page:685-699
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Tullemans Bibian M.E.¹,Karel Mieke F.A.¹,Léopold Valentine²³,ten Brink Marieke S.²,Baaten Constance C.F.M.J.¹⁴,Maas Sanne L.⁴⁵,Vos Alex F.²,Eble Johannes A.⁶,Nijziel Marten R.⁷,Vorst Emiel P.C.⁴⁵⁸⁹,Cosemans Judith M.E.M.¹,Heemskerk Johan W.M.¹,Claushuis Theodora A.M.⁷,Kuijpers Marijke J.E.¹¹⁰^ORCID

Affiliation:

1. Department of Biochemistry Cardiovascular Research Institute Maastricht Maastricht University Maastricht The Netherlands

2. Center for Experimental and Molecular Medicine Amsterdam University Medical Centres, Academic Medical Centre University of Amsterdam Amsterdam The Netherlands

3. Hopital Lariboisiere Department of Anaesthesiology and Critical Care Paris France

4. Institute for Molecular Cardiovascular Research (IMCAR) University Hospital Aachen Aachen Germany

5. Interdisciplinary Center for Clinical Research (IZKF) RWTH Aachen University Aachen Germany

6. Institute of Physiological Chemistry and Pathobiochemistry University of Münster Münster Germany

7. Department of Haematology Catharina Hospital Eindhoven Eindhoven The Netherlands

8. Department of Pathology Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre Maastricht Netherlands

9. Institute for Cardiovascular Prevention (IPEK) Ludwig‐Maximilians‐University Munich Munich Germany

10. Thrombosis Expertise Centre, Heart and Vascular Centre Maastricht University Medical Centre Maastricht The Netherlands

Funder

Hartstichting

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.269

Reference52 articles.

1. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

2. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

3. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

4. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

5. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-phased Kinetics and Interaction of Protein Kinase Signaling in Glycoprotein VI-Induced Platelet αIIbβ3 Integrin Activation and Degranulation;Thrombosis and Haemostasis;2024-04-23

2. C-type lectin-like receptor 2: roles and drug target;Thrombosis Journal;2024-03-19

3. Modelling arterial thrombus formation in vitro;Current Opinion in Hematology;2023-11-03

4. Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients;Thrombosis Research;2023-08

5. Differential Regulation of GPVI-Induced Btk and Syk Activation by PKC, PKA and PP2A in Human Platelets;International Journal of Molecular Sciences;2023-04-24